Revista de la Sociedad Argentina de Diabetes
ESTUDIO DISCOVER EN LA POBLACIÓN ARGENTINA
Resumen
Introducción: la diabetes mellitus tipo 2 (DM2) es una enfermedad metabólica de alta prevalencia que constituye un importante factor de riesgo cardiovascular, en la cual los pacientes no sólo se diagnostican tardíamente, sino que permanecen por tiempos prolongados con mal control de la glucemia y de los demás factores de riesgo cardiovascular. Se registra una significativa inercia terapéutica en la implementación de drogas antidiabéticas en la segunda línea de tratamiento.
Objetivos: el objetivo principal del estudio DISCOVER fue proporcionar datos del mundo real para evaluar la terapéutica antidiabética y los resultados clínicos prospectivos en pacientes con DM2 que inician una terapia farmacológica de segunda línea para la reducción de la glucemia.
El objetivo secundario fue informar los datos de referencia de Argentina comparados con pacientes del mundo global, incluyendo variables metabólicas, edad, antigüedad de la enfermedad, y riesgo cardiovascular.
Palabras clave
Texto completo:
PDFReferencias
I. International Diabetes Federation. IDF Atlas. Eighth Edition 2017. Disponible en: https://diabetesatlas.org/resources/2017-atlas.html. Acceso: 14 de mayo de 2019.
II. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4•4 million participants. Lancet 2016; 387:1513-30
III. Guías ALAD sobre el Diagnóstico, Control y Tratamiento de la Diabetes Mellitus Tipo 2 con Medicina Basada en Evidencia. Edición 2013. Revista de la Asociación Latinoamericana de Diabetes. Disponible en: http://www.revistaalad.com/pdfs/Guias_ALAD_11_Nov_2013.pdf. Acceso: 14 de mayo de 2019.
IV. Gakidou E, Mallinger L, Abbott-Klafter J, et al. Management of diabetes and associated cardiovascular risk factors in seven countries: a comparison of data from national health examination surveys. Bull World Health Organ 2011; 89:172-183.
V. Dall TM, Venkat-Narayan KM, Gillespie KB, et al. Detecting type 2 diabetes and prediabetes among asymptomatic adults in the United States: modeling American Diabetes Association versus US Preventive Services Task Force Diabetes Screening Guidelines. Popul Health Metr 2014; 12:12.
VI. Beagley J, Guariguata L, Weil C, et al. Global estimates of undiagnosed diabetes in adults. Diabetes Res Clin Pract 2014;103:150-160.
VII. Barcelo A, Rajpathak S. Incidence and prevalence of diabetes mellitus in the Americas. Rev Panam Salud Publica/Pan Am J Public Health 2001;10(5):300-308.
VIII. Aschner P, Aguilar-Salinas C, Aguirre L, et al. Diabetes in South and Central America: An update. Diabetes Res Clin Prac 2014;103:238-243.
IX. World Health Organization. Global Report on Diabetes. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/204871/9789241565257_eng.pdf;jsessionid=1C74650EBDD9C3BD0B2154C287D3129F?sequence=1. Acceso: 14 de mayo de 2019.
X. Pan American Health Organization. Diabetes in the Americas. Disponible en: https://www.paho.org/hq/index.php?option=com_content&view=article&id=12126:diabetes-in-the-americas&Itemid=40721〈=en. Acceso: 14 de mayo de 2019.
XI. Barquera S, Tovar-Guzman V, Campos-Nonato I, et al. Geography of diabetes mellitus mortality in Mexico: an epidemiologic transition analysis. Arch Med Res 2003; 34(5):407-414.
XII. Sánchez-Barriga JJ. Mortality trends from diabetes mellitus in the seven socioeconomic regions of Mexico, 2000–2007. Rev Panam Salud Publica 2010; 28(5):368-75.
XIII. The Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration. Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardio-metabolic risk factors between 1980 and 2010: comparative risk assessment. Lancet Diabetes Endocrinol 2014; 2(8):634-647.
XIV. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386(9995):743-800.
XV. Singh GM, Danaei G, Farzadfar F, et al. The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis. PLoS One 2013; 8: e65174.
XVI. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405-12.
XVII. 17.Gæde P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348:383-93.
XVIII. Fox CS, Hill-Golden S, Anderson CH, et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2015; 38:1777-1803.
XIX. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020 Jan 7;41(2):255-323. Doi: 10.1093/eurheartj/ehz48.
XX. Professional Practice Committee: standards of care in Diabetes 2020. Diabetes Care 2020 Jan; 43(Supplement 1):S3-S3.
XXI. International Diabetes Federation. Global Guideline for Type 2 Diabetes. Disponible en: https://www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-diabetes.html. Acceso: 14 de mayo de 2019.
XXII. Rosas-Guzmán J, Lyra R, Aguilar-Salinas CA, et al. ALAD Consensus Group. Treatment of type 2 diabetes in Latin America: a consensus statement by the medical associations of 17 Latin American countries. Rev Panam Salud Publica 2010; 28(6):463-71.
XXIII. Rathmann W, Medina J, Kosiborod M, et al. The discover study: diversity of sites, physicians, and patients (abstract). Pharmacoepidemiol Drug Saf 2018; 27(Suppl 2): S228-229.
XXIV. Escobedo J, Buitron LV, Velasco MF, et al. High prevalence of diabetes and impaired fasting glucose. Diabet Med 2009;26: 864-871.
XXV. 25.Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology. Clinical Practice Guidelines for developing a diabetes mellitus comprehensive. Care Plan 2015. Endocr Pract 2015; 21(Suppl 1):1-87.
DOI: http://dx.doi.org/10.47196/diab.v54i2.243
Copyright (c) 2020 Sociedad Argentina de Diabetes Asociación Civil
